Icatibant as acute treatment for hereditary angioedema in adults

References

• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616.
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Cicardi M, et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104(6):1321–1322.
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Bradykinin and the pathogenesis of hereditary angioedema. World Allergy Organ J. 2011;4(4):73–75.
   PubMedGoogle Scholar
• Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother. 2013;14(5):571–586.
   PubMed Web of Science ®Google Scholar
• Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–S131.
   PubMed Web of Science ®Google Scholar
• Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Kalmar L, Hegedus T, Farkas H, et al. HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat. 2005;25(1):1–5.
   PubMed Web of Science ®Google Scholar
• Rosen FS, Pensky J, Donaldson V, et al. Hereditary angioneurotic edema: two genetic variants. Science. 1965;148(3672):957–958.
   PubMed Web of Science ®Google Scholar
• van Geffen M, Cugno M, Lap P, et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol. 2012;167(3):472–478.
   PubMed Web of Science ®Google Scholar
• Bjorkqvist J, Nickel KF, Stavrou E, et al. In vivo activation and functions of the protease factor XII. Thromb Haemost. 2014;112(5):868–875.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010;47(13):2161–2169.
   PubMed Web of Science ®Google Scholar
• Speletas M, Szilagyi A, Psarros F, et al. Hereditary angioedema: molecular and clinical differences among European populations. J Allergy Clin Immunol. 2015;135(2):570–573.
   PubMed Web of Science ®Google Scholar
• Farkas H, Harmat G, Fay A, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol. 2001;81(5):376–377.
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–274.
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–697.
   PubMed Web of Science ®Google Scholar
• Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):19.
   PubMedGoogle Scholar
• Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619–627.
   PubMed Web of Science ®Google Scholar
• Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol. 2012;24(4):353–361.
   PubMed Web of Science ®Google Scholar
• Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
   PubMedGoogle Scholar
• Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5(12):182–199.
   PubMedGoogle Scholar
• Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147–157.
   PubMed Web of Science ®Google Scholar
• Zotter Z, Csuka D, Szabo E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9(1):44.
   PubMed Web of Science ®Google Scholar
• Farkas H, Kohalmi KV, Zotter Z, et al. Short-term prophylaxis in a patient with acquired C1-INH deficiency. J Allergy Clin Immunol. 2014;134:478–480.
   PubMed Web of Science ®Google Scholar
• Gower RG, Busse PJ, Aygoren-Pursun E, et al. Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J. 2011;4(2 Suppl):S9–S21.
   PubMedGoogle Scholar
• Costantino G, Casazza G, Bossi I, et al. Long-term prophylaxis in hereditary angio-oedema: a systematic review. BMJ Open. 2012;2(4):e000524–e000524.
   Google Scholar
• Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med. 1972;286(15):808–812.
   PubMed Web of Science ®Google Scholar
• Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287(9):452–454.
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011;66(2):192–196.
   PubMed Web of Science ®Google Scholar
• Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295(26):1444–1448.
   PubMed Web of Science ®Google Scholar
• Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett. 2003;86(3):271–276.
   PubMed Web of Science ®Google Scholar
• Drouet C, Desormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429–433.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med. 2012;125(9):938 e1–7.
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801–808.
   PubMed Web of Science ®Google Scholar
• Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821–827 e14.
   PubMed Web of Science ®Google Scholar
• Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007;98(4):383–388.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523–531.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532–541.
   PubMed Web of Science ®Google Scholar
• Berinert Package Insert [Internet]. 2014 [cited 2016 Feb 3]. Available from: http://www.fda.gov/downloads/…/UCM186268.pdf
   Google Scholar
• Berinert 500 IU- summary of product characteristics [Internet]. 2015 [cited 2016 Feb 3]. Available from: https://www.medicines.org.uk/emc/medicine/21650
   Google Scholar
• Cinryze Package Insert. 2014. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM129918.pdf
   Google Scholar
• ANNEX I. Summary of product characteristics. Cinryze 500 Units powder and solvent for solution for injection. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001207/WC500108895.pdf
   Google Scholar
• CHMP assessment report.Ruconest. European Medicines Agency; 2010. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001223/WC500098546.pdf
   Google Scholar
• Ruconest (C1 esterase inhibitor [recombinant]). Full Prescribing Information. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM405634.pdf
   Google Scholar
• KALBITOR® (ecallantide). Full Prescribing Information; 2015. Available from: www.kalbitor.com/hcp/rems/pdf/KalbitorFullPrescribingInformation.pdf
   Google Scholar
• ANNEX I. Summary of product characteristics. Firazyr 30 mg solution for injection in pre-filled syringe. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000899/WC500022966.pdf
   Google Scholar
• FIRAZYR® (icatibant). Full Prescribing Information; 2011. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf
   Google Scholar
• Vavrek RJ, Stewart JM. Development and modification of competitive antagonists of bradykinin. In: Deber CM, Hruby VL, Kopple KD, editors. Peptides, structure and function. Proceedings of the 9th American Peptides Symposium. Rockford (IL): Pierce Chemical Comp; 1985. p. 655–658.
   Google Scholar
• Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides. 1985;6(2):161–164.
   PubMed Web of Science ®Google Scholar
• Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102(3):769–773.
   PubMed Web of Science ®Google Scholar
• Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102(3):774–777.
   PubMed Web of Science ®Google Scholar
• Cruden NLM, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin Pharmacother. 2008;9(13):2383–2390.
   PubMed Web of Science ®Google Scholar
• Feletou M, Martin CA, Molimard M, et al. In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pharmacol. 1995;274(1–3):57–64.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Icatibant. Drugs. 2010;70(1):73–81.
   PubMed Web of Science ®Google Scholar
• Fincham CI, Bressan A, Paris M, et al. Bradykinin receptor antagonists–a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009;19(7):919–941.
   PubMed Web of Science ®Google Scholar
• Rhaleb NE, Rouissi N, Jukic D, et al. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol. 1992;210(2):115–120.
   PubMed Web of Science ®Google Scholar
• Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109(8):1057–1063.
   PubMed Web of Science ®Google Scholar
• Davis AE 3rd. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006;26(4):633–651.
   PubMed Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol. 1994;38(4):317–321.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529–537.
   PubMed Web of Science ®Google Scholar
• Bas M. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial. Expert Rev Clin Immunol. 2012;8(8):707–717.
   PubMed Web of Science ®Google Scholar
• Malbran A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014;177(2):544–553.
   PubMed Web of Science ®Google Scholar
• Bas M, Greve J, Hoffmann TK, et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy. 2013;68(11):1452–1459.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Farkas H, Moldovan D, et al. Icatibant for multiple hereditary angioedema attacks across the controlled and open-label extension phases of FAST-3. Int Arch Allergy Immunol. 2015;168(1):44–55.
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
   PubMedGoogle Scholar
• Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy. 2014;69(3):305–314.
   PubMed Web of Science ®Google Scholar
• Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013;8(2):e53773.
   PubMed Web of Science ®Google Scholar
• Maurer M, Longhurst HJ, Fabien V, et al. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc. 2014;35(5):377–381.
   PubMed Web of Science ®Google Scholar
• Hernandez Fernandez de Rojas D, Ibanez E, Longhurst H, et al. Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by health care professionals. Int Arch Allergy Immunol. 2015;167(1):21–28.
   PubMed Web of Science ®Google Scholar
• Maurer M, Church MK. Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H(1)-antihistamines. Exp Dermatol. 2012;21(2):154–155.
   PubMed Web of Science ®Google Scholar
• Rosenkranz B, Brunner-Ferber F, Knolle J. Efficacy and safety profile of the potent and selective bradykinin B2 receptor antagonist icatibant in healthy volunteers. Presented at the 26th EAACI Congress; 2007 Jun 9–13; Gothenburg, Sweden.
   Google Scholar
• Wagner F, Rosenkranz B, Knolle J. Absolute bioavailability of subcutaneously administered icatibant, a selective and potent bradykinin B2 receptor antagonist [abstract no. 1071]. J Allergy Clin Immunol. 2007;119(1 Suppl.):S274.
   Web of Science ®Google Scholar
• Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119(6):1497–1503.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Aberer W, Bouillet L, et al. Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey. Allergy Asthma Proc. 2015;36(5):399–406.
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Schicketanz KH, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10):1229–1235.
   PubMedGoogle Scholar
• Zanichelli A, Magerl M, Longhurst H, et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol. 2013;9(1):29.
   PubMed Web of Science ®Google Scholar
• Caballero T, Aygoren-Pursun E, Bygum A, et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc. 2014;35(1):47–53.
   PubMed Web of Science ®Google Scholar
• Farkas H, Kohalmi KV, Veszeli N, et al. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc. 2016;37:164–170.
   PubMed Web of Science ®Google Scholar
• Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet. 2009;374(9684):159–169.
   PubMed Web of Science ®Google Scholar
• Kalaria S, Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc. 2013;34(6):519–522.
   PubMed Web of Science ®Google Scholar
• Wiednig M. Successful treatment of acute hereditary angioedema attacks with self-administered icatibant in patients with venous access problems. BMJ Case Rep. 2013;2013:1–3.
   PubMedGoogle Scholar
• Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):22.
   PubMedGoogle Scholar
• Bernstein JA, Riedl M, Zacek L, et al. Facilitating home-based treatment of hereditary angioedema. Allergy Asthma Proc. 2015;36(2):92–99.
   PubMed Web of Science ®Google Scholar
• Farkas H, Csuka D, Zotter Z, et al. Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol. 2012;129(3):851–852 e2.
   PubMed Web of Science ®Google Scholar
• Campos RA, Valle SOR, Franca AT, et al. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study. Sao Paulo Med J. 2014;132(5):261–265.
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Mansi M, Periti G. Icatibant exposure during pregnancy in a patient with hereditary angioedema. J Investig Allergol Clin Immunol. 2015;25(6):447–449.
   PubMed Web of Science ®Google Scholar
• Farkas H, Kőhalmi KV, Veszeli N, et al. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res. 2016 Apr 19. doi:10.1111/jog.13003. [Epub ahead of print]
   PubMedGoogle Scholar
• Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308–320.
   PubMed Web of Science ®Google Scholar
• Angeletti C, Angeletti PM, Mastrobuono F, et al. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema. Int J Immunopathol Pharmacol. 2014;27(4):653–659.
   PubMed Web of Science ®Google Scholar
• Senaratne KT, Cottrell AM, Prentice RI. Successful perioperative management of a patient with C1 esterase inhibitor deficiency with a novel bradykinin receptor B2 antagonist. Anaesth Intensive Care. 2012;40(3):523–526.
   PubMed Web of Science ®Google Scholar
• Bas M, Hoffmann TK, Kojda G. Icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(19):1867–1868.
   PubMed Web of Science ®Google Scholar
• Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010;56(3):278–282.
   PubMed Web of Science ®Google Scholar